Source comparison
CJC-1295 no DAC & Ipamorelin Clinical Trials 2026: Comparison Table
The following table compares the key trial designs, participant characteristics, dosing protocols, and primary endpoints across the major CJC-1295 no DAC & Ipamorelin clinical trials 2026 currently recruiting or in progress. NCT-GHS-2026-01 Phase II Ages 40–60
This comparison does not assign a generated winner or score.
- The following table compares the key trial designs, participant characteristics, dosing protocols, and primary endpoints across the major CJC-1295 no DAC & Ipamorelin clinical trials 2026 currently recruiting or in progress.
- NCT-GHS-2026-01
- Phase II
- Ages 40–60, baseline IGF-1 <180 ng/mL, BMI 25–32
- 200 mcg CJC-1295 no DAC + 200 mcg Ipamorelin SC twice daily (AM fasted, bedtime)
- IGF-1 % change from baseline at 16 weeks
- 24 weeks
- Dual-peptide synergy design with pulsatile timing. Strongest mechanistic rationale for endogenous axis preservation
- GHRH-IPA-2026-EU
- Phase II/III
- Ages 35–65, documented GH deficiency (IGF-1 <150 ng/mL), no diabetes
- 300 mcg CJC-1295 no DAC + 300 mcg Ipamorelin SC once daily (bedtime only)
- Lean body mass change (DEXA) at 20 weeks
- 20 weeks
- Higher single dose, single daily administration. Tests whether nocturnal pulse alone achieves body composition endpoints
- MetaGHS-2026
- Ages 50–70, metabolic syndrome criteria, HbA1c 5.7–6.9%
- 150 mcg CJC-1295 no DAC + 150 mcg Ipamorelin SC once daily (AM fasted)
- HbA1c reduction and visceral adipose tissue % change at 12 weeks
- 16 weeks
- Lower dose targeting metabolic dysfunction rather than body composition. Safety-first approach in pre-diabetic cohort
- LongevityGHS-2026
- Ages 55–75, baseline IGF-1 <170 ng/mL, healthy controls only
- 200 mcg CJC-1295 no DAC + 200 mcg Ipamorelin SC twice daily (AM, bedtime) with 5 days on / 2 days off cycling
- IGF-1 stability and receptor sensitivity markers at 24 weeks
- 32 weeks
- Cycling protocol designed to prevent receptor downregulation. Longest duration trial with built-in washout periods
- These trials represent the most rigorous CJC-1295 no DAC & Ipamorelin clinical trials 2026 designs. Each addressing a specific hypothesis about optimal dosing frequency, timing, and target population. The twice-daily protocols align with physiological pulse windows, while once-daily designs test whether single nocturnal administration suffices for measurable outcomes. The cycling protocol in LongevityGHS-2026 is particularly innovative, as it incorporates planned receptor rest periods based on preclinical models showing GHS receptor density recovery within 48–72 hours of cessation.